Oncology A look back to ASCO 2025: Industry comments from iOnctura an... ASCO 2025 may be over, but the insights for the future of oncology are only just beginning.
News RNAi biotech City hauls in $200m in upsized IPO City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
